Drug Ther Bull. 2003 Apr;41(4):25-9. doi: 10.1136/dtb.2003.41425.
The introduction of combined measles, mumps and rubella (MMR) vaccine into the UK childhood immunisation schedule in 1988 has markedly reduced the incidence of these diseases and their complications, with, for example, no deaths from acute measles occurring since 1992. However, uptake of MMR vaccine has fallen since the publication, in 1998, of a study that suggested a link between exposure to the vaccine and the development of intestinal inflammation and autism. The study, and the subsequent debate, have attracted considerable media coverage and left many parents and some healthcare professionals uncertain about what to do. While in 1996, 92% of children in England and Wales had received their first dose of the vaccine by the age of 2 years, by 2001-2 this figure had fallen to 84%, with much lower uptake in some regions, threatening a resurgence of all three diseases. Here, we review the evidence for the effectiveness and safety of MMR vaccine.
1988年,麻疹、腮腺炎和风疹联合疫苗(MMR)被纳入英国儿童免疫计划,这显著降低了这些疾病及其并发症的发病率,例如,自1992年以来,急性麻疹未导致死亡。然而,自1998年一项研究发表以来,MMR疫苗的接种率有所下降。该研究表明,接种疫苗与肠道炎症和自闭症的发生之间存在联系。这项研究及随后的辩论引起了媒体的广泛报道,让许多家长和一些医疗保健专业人员对该怎么做感到不确定。1996年,英格兰和威尔士92%的儿童在2岁前接种了第一剂疫苗,但到2001 - 2年,这一数字降至84%,一些地区的接种率更低,这有可能导致这三种疾病卷土重来。在此,我们回顾MMR疫苗有效性和安全性的证据。